Lee Greenberger on Newly Approved Drugs for Multiple Myeloma
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.
Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.
Three drugs were FDA approved within 3 weeks — Darzalex (daratumumab), Ninlaro (ixazomib), and Empliciti (elotuzumab). Darzalex and Empliciti are antibodies, and Ninlaro is a proteasome inhibitor.
The agents can be used as monotherapy or in combination with conventional therapy, Greenberger explains. They have also extended progression-free survival in patients with myeloma.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
